RxDoctor Payments Data

John Shuck, MD

Cardiovascular Disease · Dover, DENPI 1689641086

Payments from drug & device makers

What this record shows

11 manufacturers reported payments, led by Canon Medical Systems USA, Inc. at 54.4% of the total. Reporting peaked in 2021 at $1,845 and has fallen 75.3% since, to $456 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in DE, where the typical reported total is $2,459.

$3,098in general payments, 2019–2025

Across 57 payments — averaging $54.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Canon Medical Systems USA, Inc.$2K
  • Mentor Worldwide LLC$544
  • AbbVie$277
  • Medtronic$206
  • Boston Scientific$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$74
  • plus $193 from 5 others

What the payments were for

  • Travel & lodging$1,61052%
  • Food & beverage$1,48848%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,098 in reported general payments places this provider in the 50th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$259,766
Medicare patients
1,703
Services billed
5,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$109,005
JardianceEmpagliflozin77$92,973
XareltoRivaroxaban35$36,680
EntrestoSacubitril/Valsartan21$34,502
VascepaIcosapent Ethyl19$13,738
BrilintaTicagrelor12$11,093
Repatha SureclickEvolocumab15$7,744
Rosuvastatin Calcium189$5,265
Ezetimibe73$3,449
Metoprolol Succinate139$2,072
Ranolazine ErRanolazine18$1,787
Amiodarone Hcl50$1,502
Atorvastatin Calcium56$871
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$718
Bumetanide13$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$109,00577 claims
AstraZenecaBrilinta$59$11,09312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →